<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

SITC20 Poster 738: New Breast Cancer Tumor Homograft Models Developed

Establishment and Application of a Series of Genetically Engineered Mouse-Derived Breast Cancer Homograft Models

Yanrui Song, Jessie Wang, Likun Zhang, Annie X An, Henry Q.X. Li, Davy X. Ouyang
#Cyagen Biosciences Inc
SITC20 Poster 738: New Breast Cancer Tumor Homograft Models Developed
Advanced preclinical models are needed for breast cancer research, to evaluate new therapeutics and to better understand tumor biology. Tumor homografts are derived from genetically engineered mouse models (GEMMs), and combine GEMM histopathological and molecular features with an improved operational efficiency and more synchronized tumor growth.

This poster details the establishment and characterization of a range of breast cancer tumor homografts from GEMMs commonly used in preclinical breast cancer research. Characterization data includes histopathological and immunohistochemical analysis, immunoprofiling, as well as benchmarking with immunotherapeutic, cytotoxic, and targeted therapies.

Download this Poster this to Discover:

  • A series of breast cancer tumor homograft models derived from GEMMs to facilitate both mechanistic investigation and preclinical testing of novel therapeutics, including TNBC, HER2+, and hormone receptor positive models

  • That immunotherapy treatment with anti-mPD-1 and anti-mCTLA-4 produced tumor growth inhibition in a triple negative model, accompanied by tumor regression

  • The varying response to cytotoxic agents across the model panel, with robust response to cisplatin observed in five models

Download the Poster Now!



Download Now

Your privacy is important to us.
We'll never share your information.